A novel potent and selective GCN2 inhibitor, APL-4098, has anti-leukemic activity through dysregulation of mitochondrial function.

Venclexta (venetoclax) - Roche, AbbVie

APL-4098 - Apollo Therap

http://www.ncbi.nlm.nih.gov/pubmed/41729725

Armin Zebisch; Bianca Perfler; Claire Seydoux; Gavin Whitlock; Holger W Auner; Kevin Blighe; Matthew J Fuchter; Monica Roman-Trufero; Nadine Clemo; Richard Butt

Feb 23, 2026